Guggenheim Maintains Buy on Relay Therapeutics, Lowers Price Target to $10

Benzinga · 05/07 15:16
Guggenheim analyst Michael Schmidt maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price target from $30 to $10.